FDA approves a CRISPR-based medicine for treatment of sickle cell disease (statnews.com)

Article summary

The FDA has approved a CRISPR-based medicine called Casgevy for the treatment of sickle cell disease, a genetic disorder that affects approximately 100,000 people in the US. The treatment, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, has been shown to eliminate recurrent episodes of debilitating pain caused by sickle cell disease. Casgevy is a potential cure for the disease, but its high cost, estimated at $2.2 million, may limit access to the treatment. The approval marks a significant milestone in the development of genetic medicines for inherited diseases.

Main themes

• CRISPR gene editing
• sickle cell disease treatment
• genetic medicine
• access to healthcare
• cost-effectiveness
• risk and safety

What commenters say

• The high cost of the treatment may limit access to it, despite its potential to be a cost-effective option in the long run.
• The use of chemotherapy as a preparatory treatment for gene therapy may pose a risk of blood cancer, but this risk may be reduced with the development of alternative chemotherapy drugs.
• Gene therapy has the potential to revolutionize the treatment of genetic diseases, but its high cost and potential risks must be carefully considered.
• The cost of the treatment is comparable to the cost of managing the disease over a patient's lifetime, but this may not make it accessible to all who need it.
• The development of gene therapy without the need for chemotherapy may be a significant step forward in making the treatment more accessible and reducing its risks.
• The stigma associated with gene therapy due to its potential risks may be a significant obstacle to its adoption, even if these risks are mitigated in the future.